Literature DB >> 34237977

Dexmedetomidine attenuates cerebral ischemia-reperfusion injury in rats by inhibiting the JNK pathway.

Bingxiao Zhao1, Da Li1, Shuchi Zhang1, Long He1, Yanqiu Ai1.   

Abstract

BACKGROUND: Cerebral ischemic reperfusion injury (CI/RI) is a common cerebrovascular disease with high morbidity and disability that threatens human health. This study was conducted to explore the effects of dexmedetomidine (Dex) on the c-Jun N-terminal kinase (JNK) pathway in CI/RI, and to provide a theoretical basis for the recovery of brain function after cerebral ischemia.
METHODS: Sprague Dawley (SD) rats (n=24) were randomly divided into Sham, Sham + Dex, Sham + yohimbine (Yoh) + Dex, Sham + SP600125, ischemic reperfusion (I/R), I/R + Dex, I/R + Yoh + Dex, and I/R + SP600125 groups, and a focal cerebral ischemia reperfusion rat model was established by linear thrombus. The neurological deficit score and infarct volume were measured. Wet/dry weight ratios were used to measure brain water content, and cerebral infarct volume was determined by 2, 3, 5-triphenyltetrazolium chloride (TTC) staining. The cellular distribution of p-JNK and cleaved caspase-3 were examined using immunofluorescent staining (IF) and the total JNK and p-JNK were determined by Western blotting (WB).
RESULTS: Compared with the Sham group, the rats in I/R, I/R + Dex, I/R + Yoh + Dex, and I/R + SP600125 groups developed hemiparesis of the left forelimb at different levels with a higher neurological deficit score, brain water content, infarct volume, and markedly upregulated expression of cleaved caspase-3, p-JNK (P<0.05). Compared with the I/R group, the neurological deficit score, brain water content, infarct volume, and expression of cleaved caspase-3, p-JNK were markedly decreased in I/R + Dex, I/R + Yoh + Dex, and I/R + SP600125 groups (P<0.05), and compared with the I/R + Dex group, the neurological deficit score, brain water content, infarct volume, and expression of cleaved caspase-3, p-JNK were markedly increased in the I/R + Yoh + Dex group (P<0.05). Double immunofluorescence staining showed there was a strong colocalization between p-JNK and the astroglial marker GFAP.
CONCLUSIONS: The JNK signaling pathway is involved in CI/RI. Inhibition of the JNK pathway blocked caspase-3 activation which can decrease CI/RI. Dex can alleviate cerebral CI/RI in rats by increasing α2-adrenergic receptor and blocking JNK phosphorylation and activation of caspase-3.

Entities:  

Keywords:  Dexmedetomidine (Dex); Jun N-terminal kinase (JNK); cerebral ischemic reperfusion injury (CI/RI)

Mesh:

Substances:

Year:  2021        PMID: 34237977     DOI: 10.21037/apm-21-1218

Source DB:  PubMed          Journal:  Ann Palliat Med        ISSN: 2224-5820


  4 in total

1.  Comparing the Effect of Dexmedetomidine and Midazolam in Patients with Brain Injury.

Authors:  Yanxia Huang; Yunxin Deng; Renjing Zhang; Mei Meng; Dechang Chen
Journal:  Brain Sci       Date:  2022-06-08

2.  MicroRNA-193b-3p reduces oxidative stress and mitochondrial damage in rats with cerebral ischemia-reperfusion injury via the seven in absentia homolog 1/Jun N-terminal kinase pathway.

Authors:  Tianye Yang; Jiajun Wu; Kui Ge; Fanlin Wang; Jingxian Fan
Journal:  Bioengineered       Date:  2022-03       Impact factor: 3.269

3.  Circular RNA cerebellar degeneration-related protein 1 antisense RNA (Circ-CDR1as) downregulation induced by dexmedetomidine treatment protects hippocampal neurons against hypoxia/reoxygenation injury through the microRNA-28-3p (miR-28-3p)/tumor necrosis factor receptor-associated factor-3 (TRAF3) axis.

Authors:  Junhua Wang; Ying Wang
Journal:  Bioengineered       Date:  2021-12       Impact factor: 3.269

4.  Dexmedetomidine reduces myocardial ischemia-reperfusion injury in young mice through MIF/AMPK/GLUT4 axis.

Authors:  Siyu Chen; Aimei Li; Jianjiang Wu; Yidan Huang; Tiantian Zou; Taiwangu Tailaiti; Jiang Wang
Journal:  BMC Anesthesiol       Date:  2022-09-14       Impact factor: 2.376

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.